Hard Cover. Zustand: Very Good. No ownership markings; a bit of staining to rear endpapers.
Sprache: Englisch
Verlag: Berlin/ Heidelberg, Springer Berlin., 1999
ISBN 10: 3540625488 ISBN 13: 9783540625483
Anbieter: Universitätsbuchhandlung Herta Hold GmbH, Berlin, Deutschland
1999. 19 x 27 cm. X, 280 S. X, 280 p. 3 illus. in color. hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, dah (Medical Radiology; Radiation Oncology). Sprache: Englisch.
Verlag: Springer,, 1999
Anbieter: Antiquariat Knacke, Berlin, Deutschland
Sprache: Englisch Pappband. Noch eingeschweißtes Exemplar!
Anbieter: Roland Antiquariat UG haftungsbeschränkt, Weinheim, Deutschland
Hardcover: 19.3 x 0 x 27 cm. 1999. 290 p. Unread book. Like new! 9783540625483 Sprache: Englisch Gewicht in Gramm: 939.
Anbieter: Basi6 International, Irving, TX, USA
Zustand: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Taschenbuch. Zustand: Neu. Progress and Perspective in the Treatment of Lung Cancer | Paul Van Houtte (u. a.) | Taschenbuch | Medical Radiology | x | Englisch | 1999 | Springer | EAN 9783540625483 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
Sprache: Englisch
Verlag: Springer Berlin Heidelberg, 1999
ISBN 10: 3540625488 ISBN 13: 9783540625483
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Lung cancer is not a single disease process but is a group of biologically variable diseases. Therefore, accurate and complete diagnosis along with complete workup of the patient prior to decision-making in treatment is essential to devise the most appropriate treatment strategy. In North America adenocarcinoma of the lung now accounts for about 40% of all lung cancers and stage for stage these tumors have a poorer prognosis than squamous cell cancers of the lung. Many prognostic indicators have been identified such as genetic markers and neuroen docrine differentiation, which have important roles to play in identifying the patients who would benefit most from active treatment. Screening and early detection have been thought to be sine qua non in early diagnosis of lung cancer. However, a number of controlled trials assessing the value of annual screening for lung cancer have demonstrated in some studies that chest X-rays and/or cytology screening may improve stage distribution, resectability, survival, and fatality but has not shown an impact on disease-specific mortality rates. The Mayo Clinic lung project compar ing quarterly chest X-rays and sputum cytology with routine care in more than 10 000 male smokers indicated that 5-year survival following treatment in the screened patients was better than rates in contemporary clinical practice. However, arguments have been ad vanced as to factors that might have biased the clinical benefits. Other trials are currently under way to deal with this issue along with new molecular markers that may enhance sputum sensitivity.
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Lung cancer is not a single disease process but is a group of biologically variable diseases. Therefore, accurate and complete diagnosis along with complete workup of the patient prior to decision-making in treatment is essential to devise the most appropriate treatment strategy. In North America adenocarcinoma of the lung now accounts for about 40% of all lung cancers and stage for stage these tumors have a poorer prognosis than squamous cell cancers of the lung. Many prognostic indicators have been identified such as genetic markers and neuroen docrine differentiation, which have important roles to play in identifying the patients who would benefit most from active treatment. Screening and early detection have been thought to be sine qua non in early diagnosis of lung cancer. However, a number of controlled trials assessing the value of annual screening for lung cancer have demonstrated in some studies that chest X-rays and/or cytology screening may improve stage distribution, resectability, survival, and fatality but has not shown an impact on disease-specific mortality rates. The Mayo Clinic lung project compar ing quarterly chest X-rays and sputum cytology with routine care in more than 10 000 male smokers indicated that 5-year survival following treatment in the screened patients was better than rates in contemporary clinical practice. However, arguments have been ad vanced as to factors that might have biased the clinical benefits. Other trials are currently under way to deal with this issue along with new molecular markers that may enhance sputum sensitivity.
Anbieter: Books Puddle, New York, NY, USA
Zustand: New. pp. x + 280 Softcover Reprint of the Original 1st Edition 1999.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 244,67
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. reprint edition. 290 pages. 10.63x0.70x7.60 inches. In Stock.
Anbieter: Mispah books, Redhill, SURRE, Vereinigtes Königreich
EUR 261,12
Anzahl: 1 verfügbar
In den WarenkorbPaperback. Zustand: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.
Anbieter: Brook Bookstore On Demand, Napoli, NA, Italien
EUR 126,26
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: new. Questo è un articolo print on demand.
Sprache: Englisch
Verlag: Springer Berlin Heidelberg Sep 2011, 2011
ISBN 10: 3642641407 ISBN 13: 9783642641404
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -'This volume provides a comprehensive account of the progress that has been made in the treatment of lung cancer. The various therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy. A balance is sought between US and European perspectives, and all of the authors are recognized experts in the field. 296 pp. Englisch.
Sprache: Englisch
Verlag: Springer, J.B. Metzler Feb 1999, 1999
ISBN 10: 3540625488 ISBN 13: 9783540625483
Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Lung cancer is not a single disease process but is a group of biologically variable diseases. Therefore, accurate and complete diagnosis along with complete workup of the patient prior to decision-making in treatment is essential to devise the most appropriate treatment strategy. In North America adenocarcinoma of the lung now accounts for about 40% of all lung cancers and stage for stage these tumors have a poorer prognosis than squamous cell cancers of the lung. Many prognostic indicators have been identified such as genetic markers and neuroen docrine differentiation, which have important roles to play in identifying the patients who would benefit most from active treatment. Screening and early detection have been thought to be sine qua non in early diagnosis of lung cancer. However, a number of controlled trials assessing the value of annual screening for lung cancer have demonstrated in some studies that chest X-rays and/or cytology screening may improve stage distribution, resectability, survival, and fatality but has not shown an impact on disease-specific mortality rates. The Mayo Clinic lung project compar ing quarterly chest X-rays and sputum cytology with routine care in more than 10 000 male smokers indicated that 5-year survival following treatment in the screened patients was better than rates in contemporary clinical practice. However, arguments have been ad vanced as to factors that might have biased the clinical benefits. Other trials are currently under way to deal with this issue along with new molecular markers that may enhance sputum sensitivity. 296 pp. Englisch.
Sprache: Englisch
Verlag: Springer Berlin Heidelberg, 2011
ISBN 10: 3642641407 ISBN 13: 9783642641404
Anbieter: moluna, Greven, Deutschland
EUR 136,16
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. With contributions by numerous experts|Comprehensive account of the progress in the treatment of lung cancerVarious therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy.
Sprache: Englisch
Verlag: Springer Berlin Heidelberg, 1999
ISBN 10: 3540625488 ISBN 13: 9783540625483
Anbieter: moluna, Greven, Deutschland
EUR 136,16
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. With contributions by numerous experts|Comprehensive account of the progress in the treatment of lung cancerVarious therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy.
Sprache: Englisch
Verlag: Springer, Springer Vieweg Feb 1999, 1999
ISBN 10: 3540625488 ISBN 13: 9783540625483
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This volume provides a comprehensive account of the progress that has been made in the treatment of lung cancer. The various therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy. A balance is sought between US and European perspectives, and all of the authors are recognized experts in the field.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 296 pp. Englisch.
Sprache: Englisch
Verlag: Springer, Springer Vieweg Sep 2011, 2011
ISBN 10: 3642641407 ISBN 13: 9783642641404
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This volume provides a comprehensive account of the progress that has been made in the treatment of lung cancer. The various therapeutic approaches are documented and appraised, with particular emphasis being placed on the benefits of a multimodality strategy. A balance is sought between US and European perspectives, and all of the authors are recognized experts in the field.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 296 pp. Englisch.
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 244,44
Anzahl: 4 verfügbar
In den WarenkorbZustand: New. Print on Demand pp. x + 280 56 Figures.
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. PRINT ON DEMAND pp. x + 280.